1. COMPLETED ACTIVITIES

1.1. Publications, guidelines and consensus documents (please send PDFs of the mentioned publications for our files; thank you):


1.2. Presentations on behalf of the Study Group at scientific meetings:

- ECCMID 2017 Vienna, ESGVH, ESCMID Networking Corner Poster ENC024

1.3. Proposals for scientific & educational sessions at ECCMID:

@ECCMID 2017 Vienna:

**Selected:**

- ECCMID 2017 Vienna 1-hour Symposium: Top papers in virology; Organizer(s): ESGVH (accepted)
- ECCMID 2017 Vienna 2-hour Symposium: Cure for viral diseases; Organizer(s): ESGVH (accepted)
- ECCMID 2017 Vienna Meet-the-Expert Session: Virological tools for hepatitis C - retreatment and resistance; Organizer(s): ESGVH (accepted)

**Not selected:**

- ECCMID 2017 Vienna 2-hour Symposium: Viral hepatitis in the immunocompromised host; Organizer(s): ESGICH, ESGVH (not selected)
- ECCMID 2017 Vienna 1-hour Symposium: HEV infection in immunosuppressed people; Organizer(s): ESGVH (not selected)
• ECCMID 2017 Vienna 1-hour Symposium: Possibilities to eradicate acute hepatitis C in Europe; Organizer(s): ESGVH (not selected)
• ECCMID 2017 Vienna 1-hour Symposium: The path towards HBV cure; Organizer(s): ESGVH (not selected)
• ECCMID 2017 Vienna 2-hour Symposium: Chronic hepatitis in the Mediterranean and in Eastern Europe; Organizer(s): ESGVH, Infectious Diseases and Clinical Microbiology Specialty Society of Turkey (EKMUD) (not selected)
• ECCMID 2017 Vienna 2-hour Symposium: Innovative strategies in funding HCV treatment; Organizer(s): ESGVH (not selected)
• ECCMID 2017 Vienna 2-hour Symposium: Remaining issues in hepatitis C; Organizer(s): ESGVH (not selected)

1.4. Organization of scientific meetings and workshops outside ECCMID:
• None

1.5. Organization of educational activities outside ECCMID:
• None

1.6. Funded research projects (especially collaborative projects):
• Participation as ESGVH with the “Hepatitis C antiviral therapy failure Registry (HepCaRe) organised by the European Society for Translational Antiviral Research (ESAR). This European database is set up to systematically collect data on anti-HCV therapy failure. 15 Centers across Europe are including patients currently totalling 371 registered in the database.

1.7. Students exchanges
• One recently graduated trainee in infectious diseases from Pavia (Prof. Mondelli) has obtained a grant to spent 6 months in Paris on HIV and HCV diseases (Nov 2016-May 2017, Prof. Salmon).
• One trainee in infectious disease from the University of Pavia (Prof. Mondelli) is spending 6 months in Prof. Joop Arends unit in Utrecht on HIV and hepatitis (Nov 2017- May 2018)

1.8. Other important activities:
• D Salmon-Ceron. Participation of ESGVH to a workshop organized by ESCMID at the XVIII Pan American Conference in Infectious Diseases, May 19 2017, Panama, Lecture on Hepatitis B diagnostic and treatment.
• Mojca Maticic. Invited speaker at the ILC/EASL 2017, Amsterdam, The Netherlands. Session entitled “Elimination of hepatitis B and C in the EU: challenges and opportunities«. Lecture: »What health system changes do we need at country level?«

PLANNED ACTIVITIES

Our planned activities for next year will be:

1. Organize scientific sessions at ECCMID 2018 (see details directly below)

2. Propose new sessions for ECCMID 2019 and for a Post-graduate Educational Course

3. Execute the study among European virologists concerning diagnosis and virological tools regarding hepatitis E.

@ ECCMID 2018 Madrid:

Selected:

• ECCMID 2018 Madrid Educational Workshop (2 hours) (Accepted): Remaining issues in hepatitis C; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis
• ECCMID 2018 Madrid Symposium (2 hour) (Accepted): New horizons in hepatitis B, D and E; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis

Not selected:

• ECCMID 2018 Madrid Symposium (2 hour) (Reserve): Worldwide elimination of viral infections by vaccination - an achievable goal?; co-arranged with: EVASG - ESCMID Vaccine SG, ESGVH - ESCMID SG for Viral Hepatitis
• ECCMID 2018 Madrid Meet-the-Expert (Not Selected): Viral Hepatitis as STI: new challenges; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis
• ECCMID 2018 Madrid Symposium (1 hour) (Partly accepted (merged)): New horizons in hepatitis B; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis
• ECCMID 2018 Madrid Symposium (1 hour) (Partly accepted (merged)): New treatments for hepatitis delta; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis

3
• ECCMID 2018 Madrid Symposium (2 hour) (Not Selected): HEV: One coin, two faces; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis
• ECCMID 2018 Madrid Symposium (2 hour) (Not Selected): Infectious risks of health tourism; co-arranged with: ESGITM - ESCMID SG for Infections in Travellers and Migrants, ESGVH - ESCMID SG for Viral Hepatitis, ESGNI - ESCMID SG for Nosocomial Infections
• ECCMID 2018 Madrid Symposium (2 hour) (Not Selected): Towards elimination of hepatitis B and C: challenge or reality; co-arranged with: ESGVH - ESCMID SG for Viral Hepatitis

Outside ECCMID

2. ADMINISTRATION

2.1. Number of current members:

67 SG members

2.2. Agenda for General Assembly/Business Meeting:

Agenda will be circulated before ECCMID 2018

3. FINANCES

3.1. Revenues and expenses

The balance sheet is approved

3.2. Balance

EUR 18,090.20 (as of end of December 2017)

Date: December 2017
Author: Mario U Mondelli